Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
CARLSBAD, Calif., Oct. 12, 2017 -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it will host an Analyst & Investor Event in Orlando, Florida on Thursday, October 26 from 7:00 a.m. to 9:00 a.m. E.T.
The meeting will include remarks from members of the SeaSpine leadership team on the company’s differentiated technologies and growth strategy, and commentary from key industry thought leaders.
A live webcast, including slide presentation, will be available on the SeaSpine website at www.investor.seaspine.com. An archived replay will also be available on the Company’s website following the meeting.
About SeaSpine
SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implant solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implant portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal implant product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.
Investor Relations Contact
Lynn Pieper Lewis
(415) 937-5402
[email protected]
